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Abstract
In a personalized treatment designed for a patient with pancreatic cancer resis-
tant to other treatments, the success of Mitomycin C (MMC) has been high-
lighted. This was revealed in a murine xenograft tumor model encompassing
pancreatic adenocarcinoma cells extracted from the patient. The patient was
found to exhibit a biallelic inactivation of the PALB2 gene, involved in DNA
repair in addition to another mutation in the TSC2 gene that induces suscepti-
bility of the tumor to therapeutic targets of the PI3K-mTOR pathway. The aim
of the study was to apply metabolomics to elucidate the modes of action of
each therapy, suggesting why MMC was so successful in this patient and why it
could be a more popular choice in future pancreatic cancer treatment. The
effectiveness of MMC compared to rapamycin (RM), another relevant thera-
peutic agent has been evaluated through liquid- and gas-chromatography mass
spectrometry-based metabolomic analyses of the xenograft tumors. The relative
concentrations of many metabolites in the xenograft tumors were found to be
increased by MMC relative to other treatments (RM and a combination of
both), including a number that are involved in central carbon metabolism
(CCM). Metabolic fingerprinting revealed statistically significantly altered path-
ways including, but not restricted to, the pentose phosphate pathway, glycolysis,
TCA cycle, purine metabolism, fatty acid biosynthesis, in addition to many sig-
nificant lipid and amino acid alterations. Given the genetic background of the
patient, it was expected that the combined therapy would be most effective;
however, the most effective was MMC alone. It is proposed that the effective-
ness of MMC is owed to its direct effect on CCM, a vital region of tumor
metabolism.
Abbreviations
AAALAC, Association for Assessment and Accreditation of Laboratory Animal
Care; CCM, central carbon metabolism; CV1, cross-validation; FAME, fatty acid
methyl ester; FAS, Fatty acid synthase; GC-MS, gas chromatography–mass spec-
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Introduction
Despite significant advances in understanding the molecu-
lar basis of pancreatic cancer, there has been little pro-
gress in the treatment of the disease (Jones et al. 2008;
Hidalgo 2010). Since pancreatic cancer is symptomless in
its early stages, diagnosis often occurs after metastasis to
other organs. Therefore, treatment of pancreatic cancer
usually begins with surgery to remove the main risk and
patients are subsequently treated with either radio- or
chemotherapy. Treatments currently employed are not
always definitive and may not be achievable, depending
on the aggressiveness of the tumor.
Approximately 10% of all cases of pancreatic cancer
occur due to a genetic predisposition to the disease
(Vincent et al. 2011). For example, as part of our studies
in personalized treatment of patients with pancreatic
cancer, we identified a patient who exhibited resistance to
the commonly used treatment for pancreatic cancer: gem-
citabine, and had only a 3-month life expectancy. The
patient was treated with Mitomycin C (MMC) selected
due to its success on a murine xenograft model (Avatar
model) generated from pancreatic adenocarcinoma cells
extracted from the patient. Following treatment, the
tumor marker CA19-9 was restored to normality in
3 years and the patient was apparently symptom free. To
reveal the mode of action of MMC in this case, genomic
studies were undertaken, revealing that the patient exhib-
ited a biallelic inactivation of the PALB2 gene, which is
involved in DNA repair. This was further proved by test-
ing the treatment with the wild-type PALB2 gene, which
showed resistance to MMC. We showed that this muta-
tion is associated with susceptibility to alkylating agents
such as MMC, and in fact that patient had a very good
clinical response and survival with this class of agents. In
addition to this mutation, there was another mutation in
the TSC2 gene (Villarroel et al. 2011). It has been previ-
ously shown that mutations in this gene result in hyper-
activation of the phosphoinositide 3-kinase/ mammalian
target of rapamycin (PI3K-mTOR) pathway and confer
susceptibility to inhibitors of these targets (Franz and
Weiss 2012). The purpose of this research was to deter-
mine the effects of MMC and rapamycin (RM), a known
target of the PI3K-mTOR pathway, as well as to a combi-
nation of both agents in the treatment of pancreatic can-
cer with this genetic background.
To better understand the effects of MMC, RM, and a
combination of these treatments, the murine xenograft
Avatar model described was applied to a metabolomics
study employing both gas chromatography–mass spec-
trometry (GC-MS) and liquid chromatography–mass
spectrometry (LC-MS). The aim of the study was to
reveal phenotypic effects of each treatment and to
propose why MMC was the most effective treatment,
while other treatments were less effective. For both analyt-
ical platforms, pancreatic extract samples were prepared
from the murine xenografts in four different experimental
groups: those treated with MMC, RM, MMC+RM or not
treated (NT). Samples were collected in triplicate from
three different mice in each group resulting in nine repli-
cates and metabolite extracts from each were analyzed
using both mass spectrometry techniques. The approach
involved metabolic fingerprinting, a top-down approach
to reveal phenotypic information with no particular
expectations regarding the metabolomes of each group.
The relative concentrations of many metabolites in the
xenograft tumors were found to be increased by MMC
relative to the other treatment groups, including a num-
ber that are involved in central carbon metabolism
(CCM).
Materials and Methods
An avatar mouse model (JH033) from a patient with pan-
creatic cancer and mutations in the PALB2 and TSC2
genes and this system was used for these experiments.
Immunocompromised mice (Harlan, Sant Feliu de
Codines, Spain) between 4 and 6 weeks of age were
housed on irradiated corncob bedding (Teklad, Sant Feliu
de Codines, Spain) in individual HEPA-ventilated cages
(Sealsafe Plus, Techniplast, Buguggiate, Italy) on a 12-h
light–dark cycle at 21–23°C and 40–60% humidity. Mice
were fed water and libitum (reverse osmosis, 2 ppm Cl2)
and an irradiated standard rodent diet (Teklad 2919) con-
sisting of 16% protein, 4% fat, and 4% fiber. Animals
were implanted bilaterally on the right and left flank with
tumor fragments. Prestudy tumor volumes were recorded
for each experiment beginning 1 week prior to its esti-
mated start date. When tumors reached ~150–250 mm3;
animals were matched by tumor volume into treatment
and control groups and dosing was initiated. Mice were
ear tagged and followed individually throughout the
experiment. MMC was administered at a dose of 5 mg/kg
i.p. from day 1 and RM at a dose of 4 mg/kg daily for
10 days by oral gavage (p.o.). The study protocol was
reviewed and approved by the Institutional Animal Care
and Use Committee (IACUC). During the study, both the
care and use of animals were conducted in accordance
with the regulations of the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC).
After inoculation, the animals were checked daily for
morbidity and mortality including mobility, food and
water consumption, body weight gain/loss (body weights
were measured twice weekly or every other day), eye/hair
matting, and any other abnormal effect. Death and
observed clinical signs were recorded on the basis of the
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numbers of animals within each subset. Tumor sizes were
measured twice weekly in two dimensions using a calliper,
and the volume was expressed in mm3 using the formula
TV = width2 9 length 9 0.5. At study completion,
tumor growth inhibition (% TGI) values were calculated
and reported for each treatment group (T) versus control
(C) using initial (i) and final (f) tumor measurements by
the equation: % TGI = 1  [(Tf  Ti)/(Cf  Ci)]. TGI
were compared between treated and control groups using
a two-tailed “t-test.”, where P < 0.05 was considered sta-
tistically significant.
Chemicals
Information regarding all reagents and solvents used in
this study are described in Data S1.
Metabolic fingerprinting by GC- and LC-MS
Metabolic fingerprinting of tissue samples (36 samples: 9
per treatment) was performed using both GC- and LC-
MS. Full methods are supplied in Data S1 for the prepa-
ration of samples, fingerprinting, and data processing by
each technique.
Data analysis
Samples were divided into four groups relating to the
treatment (MMC, MMC+RM, RM, NT), and compared.
Comparison of groups was performed according to the
different effect of the treatments under study. Firstly, a
comparison was made between MMC-treated tumors ver-
sus all other experimental groups collectively. Subse-
quently, the metabolic fingerprints from tumors treated
with MMC were compared to the metabolic profiles from
tumors treated with the combined MMC and RM treat-
ment, with RM or to NT samples. All four comparisons
were used to elucidate the mode of action of MMC with
regard to its effect on tumor metabolism.
Differences between metabolites in different groups
were evaluated by univariate data analysis followed by a
multivariate analysis. Univariate analyses were performed
using unpaired t-tests with P-value <0.05 to consider
metabolites with significant differences in the mean peak
area for every metabolite between the groups. For each
biological comparison, the P-values from both LC-MS
and GC-MS analyses were collectively corrected using the
Benjamini and Hochberg (1995) approach to control the
false discovery rate.
Subsequently for classification, multivariate analysis was
performed using SIMCA P+ 12.0.1 software (Umetrics,
Umea˚, Sweden). Principal components analysis (PCA)
and orthogonal partial least squares regression discrimi-
nant analysis (OPLS-DA) were performed on log trans-
formed and Pareto scaled data (LC-MS) or non-
transformed, UV-scaled data (GC-MS). Transformation
and scaling of data were chosen based on suitability for
each dataset. To detect trends, outliers, and the quality of
the data acquisition, PCA was performed. To discriminate
between groups and to identify the compounds responsi-
ble, the supervised methods OPLS-DA were performed.
All OPLS-DA models were cross-validated by internal
cross-validation (CV1) in SIMCA P+. Finally, the percent-
age of change, using MMC group as control, was calcu-
lated for statistically significantly different metabolites of
each comparison.
Results
Effect of the treatment in the morphometry
of the tissue
Figure 1 shows the TGI curves of Avatar models treated
with the agents at the indicated doses and schedules. As
expected, MMC was very effective with a TGI of 104%.
However, RM showed only moderate activity with a TGI of
64%. Unexpectedly, the combination was ineffective with a
TGI of 31% suggesting that blocking of mTOR induced
resistance to the DNA damaging actions of MMC.
Figure 1. Tumor growth profiles of Avatar model JH033 treated with
Mitomycin C and rapamycin. The graph shows the relative tumor
volume measured at 8 time points (%, with respect to the tumor
volume at the treatment day 1) of the four experimental groups as
described in the graph legend. The tumor growth inhibition (TGI),
calculated at treatment day 30, is also shown. (MMC, Mitomycin C;
i.p., intraperitoneal; p.o., per os; qd910, every day during 10 days).
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Statistical analysis and modeling
LC-MS
The alignment of all masses detected from quality con-
trols (QCs) and pancreas extract samples was the first
step of data treatment. This was performed for retention
time (RT) in the range 0.48–36 min, where the RT win-
dow was 0.5 min and the mass window was 20 ppm. This
alignment step generated the data matrix with abundances
for 57,936 potential compounds in the first comparison
(all other groups [OG] versus MMC), 45,902 for the
MMC+RM versus MMC comparison, 48,595 for the RM
versus MMC comparison, and 49,877 for the NT versus
MMC comparison.
The effect of random signals was minimized using a fil-
ter that includes only features present in a minimum
number of samples in one of the groups (75%). After fil-
tering, the data matrix contained 1718 different variables
for the OG versus MMC comparison, 2035 for
MMC+RM versus MMC, 1979 for RM versus MMC, and
2213 for the NT versus MMC comparison.
Univariate analysis (t-tests) revealed 318 variables with
significant differences in the mean between OG versus
MMC, 495 between MMC+RM versus MMC, 517
between RM versus MMC, and 789 between NT versus
MMC. These variables were used in multivariate analysis
(SIMCA P+ 12.0.1 software). The PCA model was esti-
mated to check the grouping of samples and also to test
the quality of the analysis. The PCA plots displayed in
Figure 2A show clustering of QC samples in both analyses
and neither contained statistical outliers.
To preserve the characteristics of each group and
maximize significant difference, a supervised model was
required. Four OPLS-DA models were evaluated to
explain the differences in the comparisons: OG versus
MMC, MMC+RM versus MMC, RM versus MMC, and
NT versus MMC. All OPLS-DA models show good sepa-
ration between groups with strong R2 and Q2 coefficients
and no outliers can be observed in the Hotelling dia-
grams (Fig. 2B). To evaluate the significant variables for
each OPLS-DA model, a Jackknifed confidence interval
estimative with a 95% level of confidence was per-
formed.
A list of 176 variables were obtained and compared in
the OG versus MMC after Jackknifed confidence interval
test. A total of 266 variables were obtained from the
MMC+RM versus MMC comparison, 266 between RM
versus MMC, and 277 between NT versus MMC after
Jackknifed confidence interval test. All these variables
were checked against MASSTRIX and the METLIN data-
base and where possible, putative identifications were
assigned.
GC-MS
There was one analytical outlier observed in the GC-MS
data and therefore this sample was not processed as the
others and was not included in statistical analysis. This
sample was in the RM-treated experimental group. GC-
MS data, processed by AMDIS and MPP, provided 140
identified and aligned compounds. Among these metabo-
lites, 4 (i.e., from solvent, fatty acid methyl ester (FAME)
mix, blanks), 19 (with low abundant and steady peaks),
and 9 (AMDIS false-positive identification) were
excluded. Then, data were filtered by frequency keeping
the compounds present at least in the 75% of the com-
pared groups and nine additional compounds were
rejected. Subsequently, missing values were imputed, the
32 derivatives summed, and the data normalized by the
IS (methyl stearate). From the 99 compounds obtained in
the previous steps, 48 (MMC vs. NT), 31 (OG vs. MMC),
23 (RM vs. MMC), and 27 (MMC+RM vs. MMC) were
found to be statistically significant in the t-test (P < 0.05)
and were used in the multivariate data analysis.
As for LC-MS, the four groups under investigation
(MMC, MMC+RM, RM, and NT) were compared by
OPLS-DA analysis (Fig. 2C). The metabolites responsible
for the discrimination after Jackknifed confidence interval
were: 48 (MMC vs. NT), 30 (OG vs. MMC), 22 (RM vs.
MMC), and 27 (MMC+RM vs. MMC). Tables 1–4 sum-
marize the most significant metabolites identified in both
GC-MS and LC-MS from statistical analysis of each com-
parison described.
Discussion and Conclusions
Biological significance of putative
biomarkers
The most effective treatment was observed in pancreatic
tumor xenografts treated with MMC. It was shown previ-
ously in a patient with advanced pancreatic cancer exhib-
iting a biallelic inactivation of the DNA repair gene:
PALB2, that MMC is a highly effective DNA damaging
agent for reducing tumor size and prolonging prognosis
(Villarroel et al. 2011). This is a key example of the suc-
cess of personalized cancer treatment and following
PALB2 gene sequencing in other patients, if they too exhi-
bit similar genotypes, it is likely that MMC can also be
successful in their treatment. It is possible that as a conse-
quence of increased DNA damage, MMC also causes met-
abolic effects that could be biomarkers of the pancreatic
tumor response. Interestingly, the combination of MMC
and RM gave significantly worst results than MMC alone
against the expectations. To elucidate the effect of MMC
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on pancreatic tumor metabolism, these tumors were com-
pared to other treatments to reveal the metabolic differ-
ences owed to the effectiveness of MMC. Tables 1–4
highlight the results from these comparisons showing
which metabolites are significantly increased or decreased
with MMC relative to other treatments.
Firstly, a comparison was made between MMC-treated
tumors versus all other experimental groups collectively
(Table 1). Subsequently, the metabolic profiles from
tumors treated with MMC were compared to the metabolic
profiles from tumors treated the combined MMC and RM
treatment (Table 2) or with RM (Table 3) as well as to
tumors that received no treatment (Table 4). All four com-
parisons were used to elucidate the mode of action of
MMC with regard to its effect on tumor metabolism.
Observing the effects of treatments through metabolo-
mics is highly valuable in personalized medicine as it
allows the specific assessment of their action on the phe-
notype of the patient in question. The treatments pre-
sented in this research are not novel themselves; however,
their effect on this specific phenotype and their final
effects on metabolic phenotype are. The results presented
highlight the potential of metabolomics in assessing per-
sonalized medicines and reveal the potential of drug
repurposing in personalized medicine.
Many of the significant differences between the meta-
bolic profiles of MMC-treated tumors and any other
tumors were features of, or features associated with,
CCM. This is a vital metabolic subnetwork in cancer
metabolism and has been explored extensively over dec-
ades of cancer research (Warburg et al. 1927; Richardson
et al. 2008). It centers on glycolysis and the tricarboxylic
acid (TCA) cycle and involves other pathways that either
deliver molecules to be catabolized to produce energy, or
that use the carbon for the biosynthesis of other com-
pounds. These connected pathways include the pentose
phosphate pathway, amino acid metabolism, purine
metabolism, fatty acid biosynthesis, and lipid metabolism
including the synthesis of (glyco)sphingolipids and cera-
mide metabolism. MMC treatment was associated with
significant alterations in the concentrations of metabolites
from all of these pathways and therefore can be consid-
ered to have a relatively broad-spectrum action. This
could explain why the treatment is so effective, such that
a range of vital processes are targeted. The increase in
CCM metabolites that was observed could be indicative
that Mytomycin C directly inhibits pathways such as the
TCA cycle and that in the absence of efficient cycling,
metabolites accumulate. Alternatively, it could be that in
response to the treatment, tumors focus their metabolism
to conserve vital pathways and suspend functions such as
lipid synthesis that may not be crucial for tumor survival.
Carnitine and acylcarnitines were revealed as significant
changes in the responses of this metabolic phenotype to
MMC. They are important precursors in energy metabo-
lism and are essential for the transport of long-chain fatty
acids (Malaguarnera et al. 2006). The concentration of
(acyl)carnitines and carnitine precursors such as lysine
and methionine can vary depending on intake from diet
or alterations in their endogenous biosynthesis (Mala-
guarnera et al. 2006). In this case, it is likely that MMC
alters the synthesis of acylcarnitines and that different
derivatives are more or less significant depending on
which treatment it is compared to. When compared to
RM treatment and OG collectively, MMC appears to
increase acylcarnitines. When compared to the combined
treatment, MMC increases two acylcarnitines but the
combined treatment increases three. Furthermore, the lat-
ter are associated with a higher percent change from the
combined treatment. It is known that CPT1, an enzyme
catalyzing the reaction converting carnitine and acetyl-
coA to acylcarnitine, causes a resistance to RM and that it
induces fatty acid oxidation (Fingerhut et al. 2001). If
MMC is able to upregulate the activity of this enzyme, it
could explain why acylcarnitines are increased with MMC
relative to RM treatments, but also could provide evi-
dence for why RM seems to be inhibited in the combined
treatment since CPT1 involves resistance to RM. Further
evidence to support this is that in any comparison high-
lighting significant difference in fatty acids, they are
always decreased with MMC, which could suggest that
fatty acid oxidation is elevated with this treatment.
Figure 2. Multivariate analysis of metabolic fingerprints. (A) Principal components analysis (PCA) plots generated from all the samples including
the quality controls (QC) samples in gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–mass spectrometry (LC-MS)
experiments.○ – All samples + Quality controls. GC-MS model (R2 = 0.836, Q2 = 0.708) for all samples (n = 35) and QCs (n = 5); LC-MS model
(R2 = 0.746, Q2 = 0.594) for all samples (n = 36) and QCs (n = 7). (B) Orthogonal partial least squares regression discriminant analysis (OPLS-DA)
plots generated from the different comparisons under investigation (LC-MS). ■ – Other groups (n = 27) ♢ – Mitomycin C (MMC) (n = 9) ● – No
treatment (n = 9) ▲ – Rapamycin (RM) (n = 9) Δ – RM + MMC (n = 9). Other groups (OG) versus MMC model (R2X = 0.589, R2Y = 0.965,
Q2 = 0.778); not treated (NT) versus MMC model (R2X = 0.687, R2Y = 0.991, Q2 = 0.973); RM versus MMC model (R2X = 0.655, R2Y = 0.985,
Q2 = 0.931); RM+MMC versus MMC model (R2 = 0.639, R2Y = 0.986, Q2 = 0.933). (C) OPLS/O2PLS-DA plot generated from the different
comparisons under investigation (GC-MS). ■ – Other groups (n = 27) ◊ – MMC (n = 9) ● – No treatment (n = 9) ▲ – RM (n = 8) Δ – RM + MMC
(n = 9). OG versus MMC model (R2X = 0.827, R2Y = 0.898, Q2 = 0.684); NT versus MMC (R2X = 0.791, R2Y = 0.925, Q2 = 0.76); RM versus
MMC model (R2X = 0.783, R2Y = 0.96, Q2 = 0.861); RM+MMC versus MMC model (R2X = 0.889, R2Y = 0.947, Q2 = 0.555).
2014 | Vol. 2 | Iss. 6 | e00067
Page 6
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Personalized Treatment in Pancreatic Cancer A. Navarrete et al.
Many amino acids were observed as significant markers
of MMC action in this metabolic phenotype. For exam-
ple, those that function in cysteine and methionine
metabolism and/or glycine, serine, and threonine metabo-
lism were also significantly increased in tumors treated
with MMC. The metabolic pathway that connects methio-
nine to glycine via homocysteine and serine is closely
linked with the metabolism of (glycol)sphingolipids and
ceramides (Huang et al. 2011). When compared to the
combined MMC + RM treatment, MMC increases the
concentration of (keto)sphingosine and decreases cera-
mide. Similarly, ceramide levels are lower in MMC-trea-
ted tumors than in RM-treated tumors. It is known that
cellular stress can increase ceramide and that this is a
marker of cytotoxicity (Reynolds et al. 2004; Guillermet-
Guibert et al. 2009; Huang et al. 2011). The balance
between ceramide and sphingosine may shed light on the
level or severity of this. Treatments involving RM were
associated with an elevation in ceramide, while MMC
appeared to increase (keto)sphingosine. This could sug-
gest that RM is more cytotoxic; however, since MMC is
known to be more effective, targeting ceramide metabo-
Table 1. OG versus MMC.
Associated pathway Metabolite Technique
Target ion m/z
(GC) – MW (LC) RT (min) % Change P-value
Pentose phosphate pathway/
glycolysis
Glycerol-1-phosphate GC-MS 357 15.93 47 0.01
Ribulose-5-phosphate GC-MS 357 19.52 40 0.02
Glucose-6-phosphate GC-MS 73 21.31 69 0.004
Purine metabolism Hypoxanthine GC-MS 265 16.44 37 0.01
Xanthine GC-MS 353 18.57 50 0.004
TCA cycle Succinate GC-MS 147 10.46 42 0.002
Malate GC-MS 147 12.73 30 0.04
(Iso)citrate GC-MS 273 16.54 38 0.01
Arginine and proline
metabolism/alanine,
aspartate and glutamate
metabolism
Proline GC-MS 70 8.62 26 0.03
Aspartate GC-MS 73 11.94 45 0.009
Aminomalonate GC-MS 73 12.51 48 0.005
(Pyro)glutamate GC-MS 156 13.17 40 0.01
Glutamine GC-MS 246 14.30 40 0.01
Asparagine GC-MS 73 14.91 54 0.005
Putrescine GC-MS 174 15.71 49 0.01
Ornithine GC-MS 142 16.55 59 0.005
Phenylalanine metabolism Phenylalanine GC-MS/LC-MS 120/165.0792 13.54/0.75 38/24 0.009/0.03
Phenylpyruvate LC-MS 164.047 0.69 24 0.01
Tyrosine GC-MS/LC-MS 179/181.0739 17.30/0.7 42/27 0.0003/0.05
Valine, leucine, and
isoleucine degradation
Valine GC-MS 72 7.3 35 0.009
Leucine GC-MS 86 8.26 42 0.02
Cysteine and methionine
metabolism/glycine, serine
and threonine metabolism
Glycine GC-MS 102 7.74 40 0.01
Serine GC-MS 116 9.69 44 0.005
Methionine GC-MS 104 11.8 61 0.009
Lysine degradation/carnitine
metabolism
Lysine GC-MS/LC-MS 174/146.1051 17.64/0.57 58/23 0.005/0.02
Pipecolate LC-MS 129.0802 0.57 19 0.04
Stearoylcarnitine LC-MS 427.3658 21.23 33 0.05
Fatty acid biosynthesis/beta-
alanine metabolism/lipid
metabolism
Acetylspermidine LC-MS 187.1681 0.58 37 0.01
Diacetylspermine LC-MS 286.2371 0.58 43 0.01
Uracil GC-MS 241 10.77 42 0.005
LPS (18:1) LC-MS 523.2922 22.65 106 0.02
LPS (18:0) LC-MS 525.3076 25.63 79 0.01
LPE (22:6) LC-MS 525.2853 18.11 72 0.01
LPE (22:4) LC-MS 529.3174 21.1 49 0.01
PC (30:1)/PE (33:1) LC-MS 703.5113 19.36 55 0.04
PC (38:6)/PE (41:6) LC-MS 805.5685 21.57 202 0.05
PC (34:4)/PE (37:4) LC-MS 753.5309 34.86 107 0.05
PG (34:1) LC-MS 765.5590 31.56 130 0.01
Metabolites found to be statistically significantly different in all other groups compared to Mitomycin C. All P-values are those corrected using the
Benjamini–Hochberg approach for control of false discoveries. GC-MS, gas chromatography–mass spectrometry; LC-MS, liquid chromatography–
mass spectrometry; MMC, Mitomycin C; OG, other groups.
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lism is less effective than pathways such as CCM. Sphin-
gosine kinase-1 is a commonly overexpressed enzyme in
pancreatic cancer that catalyzes the reaction between cera-
mide and sphingosine-1-phosphate (Guillermet-Guibert
et al. 2009). A phenotype exhibiting elevated sphingosines
relative to ceramides due to increased sphingosine kinase
activity has been associated with chemoresistance to other
chemotherapeutic agents (Guillermet-Guibert et al. 2009).
However, although cells may be responding to the treat-
ment in this way (since MMC is effective) it could be that
this mechanism for resistance is not successful.
Purine metabolism was highlighted through the signifi-
cantly higher concentrations of xanthine, hypoxanthine,
and inosine in tumors treated with MMC compared to
other treatments. It has been suggested previously that
xanthine can serve as an electron donor for the xanthine
oxidase catalyzed reduction of MMC; thus, it functions
similar to NAD(P)H (Pan et al. 1984).
It was expected that the combination of MMC and RM
would be more effective than MMC alone; however, it
may be possible that these drugs counteract each other.
For example, RM is known to target the PI3K-mTOR
pathway. This pathway is involved in a multitude of bio-
logical processes related to cell growth and metabolism.
In particular, the role of mTOR in lipid biosynthesis has
been reviewed (Laplante and Sabatini 2009). Since RM
Table 2. MMC+RM versus MMC.
Associated pathway Metabolite Technique
Target ion m/z
(GC) – MW (LC) RT (min) % Change P-value
Pentose phosphate pathway/
glycolysis
Glycerone phosphate GC-MS 315 15.73 58 0.05
Glycerol-1-phosphate GC-MS 357 15.93 52 0.007
Purine metabolism Hypoxanthine GC-MS 265 16.44 33 0.03
Xanthine GC-MS 353 18.57 52 0.01
TCA cycle Succinate GC-MS 147 10.46 39 0.009
Fumarate GC-MS 245 10.94 39 0.009
Malate GC-MS 147 12.73 44 0.009
(Iso)citrate GC-MS 273 16.54 37 0.03
Arginine and proline metabolism/
alanine, aspartate and glutamate
metabolism
Aspartate GC-MS 73 11.94 39 0.04
Aminomalonate GC-MS 73 12.51 46 0.02
(pyro)glutamate GC-MS 156 13.17 37 0.02
Glutamine GC-MS 246 14.30 46 0.01
Asparagine GC-MS 73 14.91 57 0.009
Putrescine GC-MS 174 15.71 57 0.004
Ornithine GC-MS 142 16.55 61 0.006
Phenylalanine metabolism Tyrosine GC-MS 179 17.3 31 0.05
Valine, leucine, and isoleucine
degradation
Valine GC-MS 72 7.3 29 0.03
Leucine GC-MS 86 8.26 36 0.04
Lysine degradation/carnitine
metabolism
Lysine GC-MS 174 17.64 59 0.008
Pipecolate LC-MS 129.0794 0.57 33 0.002
Propanoylcarnitine LC-MS 217.132 0.71 40 0.002
Butyrylcarnitine LC-MS 231.1482 0.75 25 0.01
Tetradecanoylcarnitine LC-MS 371.3029 18.14 56 0.0006
Linoelaidyl carnitine LC-MS 423.3343 17.27 53 0.04
Fatty acid biosynthesis/beta-alanine
metabolism/lipid metabolism
Uracil GC-MS 241 10.77 44 0.002
PI (42:0) LC-MS 936.7118 32.46 59 0.02
PS (42:0) LC-MS 875.6528 32.59 65 0.01
LPE (18:0) LC-MS 481.3169 23.06 50 0.004
LPE (22:4) LC-MS 529.3174 21.11 64 0.01
LPE (22:5) LC-MS 527.3037 19.07 57 0.02
LPE (22:6) LC-MS 525.2854 18.11 63 0.01
Ceramide and (glyco)sphingolipid
metabolism
(Keto)sphingosine LC-MS 285.2695 14.56 59 0.005
NeuAc(a)Gal(b)-Cer(d34:2) LC-MS 1128.801 27.6 51 0.003
Prostaglandins Glyceryl-PG D2/E2/H2 LC-MS 426.2588 6.23 52 0.009
Methyl-PG A2/D2 LC-MS 348.2276 20.62 82 0.04
PG A1 LC-MS 318.2171 19.11 57 0.03
Metabolites found to be statistically significantly different in the combined Mitomycin C and Rapamycin treatment compared to Mitomycin C. All
P-values are those corrected using the Benjamini–Hochberg approach for control of false discoveries. GC-MS, gas chromatography–mass spec-
trometry; LC-MS, liquid chromatography–mass spectrometry; MMC, Mitomycin C; RM, rapamycin.
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blocks the PI3K-mTOR pathway in a way that should
inhibit the biosynthesis of lipids, it would be expected
that lipids not be exposed as features in groups involving
RM treatment. However, the converse was true. A range
of lipids including fatty acids, triglycerides, lysopho-
sphoethanolamines, phosphatidylinositol, phosphatidyl
erines and phosphocholines were found to be significantly
lower in MMC-treated tumors than in RM-treated
tumors. This could suggest that RM is less effective than
MMC at reducing lipid synthesis or that MMC inhibits
the action of RM on the PI3K-mTOR pathway.
Fatty acids such as octadecanoic acid, hexadecanoic acid,
nonadecadienoic acid and tetradecanoic acid were signifi-
cantly reduced with MMC compared to tumors that
received no treatment. Fatty acid synthase (FAS), which is
used to catalyze the synthesis of many fatty acids and is
commonly overexpressed in solid tumors, has been previ-
ously described as a marker of pancreatic adenocarcinoma
(Walter et al. 2009). This explains why the concentration
of fatty acids is elevated in the nontreated pancreatic tumor
samples and suggests that MMC may be effective in reduc-
ing the activity of FAS in a way to reduce tumor function.
Table 3. RM versus MMC.
Associated pathway Metabolite Technique
Target ion m/z
(GC) – MW (LC) RT (min) % Change P-value
Pentose phosphate pathway/glycolysis Glucose-6-phosphate GC-MS 73 21.31 74 0.6*
Purine metabolism Hypoxanthine GC-MS 265 16.44 36 0.03
Xanthine GC-MS 353 18.57 42 0.009
Inosine GC-MS 73 23.37 52 0.1
TCA cycle Succinate GC-MS 147 10.46 44 0.03
Arginine and proline metabolism/alanine,
aspartate and glutamate metabolism
Alanine GC-MS 116 7.47 46 0.03
Aspartate GC-MS 73 11.94 37 0.001
Aminomalonate GC-MS 73 12.51 43 0.05
Ornithine GC-MS 142 16.55 49 0.03
Phenylalanine metabolism Phenylalanine GC-MS 120 13.54 39 0.2*
Tyrosine GC-MS 179 17.3 39 0.03
Valine, leucine, and isoleucine degradation Valine GC-MS 72 7.3 31 0.03
Cysteine and methionine metabolism/
glycine, serine and threonine metabolism
Glycine GC-MS 102 7.74 35 0.04
Serine GC-MS 116 9.69 46 0.2*
Methionine GC-MS 104 11.8 71 0.1*
Lysine degradation/carnitine metabolism Lysine GC-MS 174 17.64 38 0.05
Pipecolate LC-MS 129.0794 0.57 25 0.001
Methylbutyroyl-carnitine LC-MS 245.1637 0.78 38 0.01
Fatty acid biosynthesis/beta-alanine
metabolism/lipid metabolism
10-hydroxycaprilate GC-MS 73 16.33 71 0.04
Acetylspermidine LC-MS 187.1682 0.58 44 0.003
Linolenate LC-MS 278.2245 26.11 67 0.04
Anandamide (18:3) LC-MS 321.2669 28.19 64 0.003
Octadecylphosphocholine LC-MS 435.3546 32.4 29 0.05
PC (20:1) LC-MS 563.3495 0.82 49 0.003
PC (36:6)/PE (39:6) LC-MS 777.5306 31.18 71 0.04
PG (43:4) LC-MS 868.6138 0.8 35 0.005
LPC (18:2) LC-MS 519.3309 18.88 173 0
LPC (18:3) LC-MS 517.315 16.23 68 0.001
LPC (20:4) LC-MS 543.3325 18.33 58 0.02
LPC (20:5) LC-MS 541.317 15.83 33 0.03
LPC (22:5) LC-MS 569.3476 19.24 62 0.02
LPS (18:1) LC-MS 523.2927 22.65 103 0.01
LPS (18:2) LC-MS 521.276 19.46 92 0.04
Ceramide and (glyco)sphingolipid
metabolism
LacCer(d38:0) LC-MS 919.6808 32.48 68 0.05
NeuAc(a)Gal(b)-Cer(d44:2) LC-MS 1128.801 27.6 27 0.05
Ganglioside GM3 (d18:0/22:0) LC-MS 1238.813 35.62 76 0.03
Prostaglandins Glyceryl-PG D2/E2/H2 LC-MS 426.2586 6.25 43 0.03
Metabolites found to be statistically significantly different in the Rapamycin treatment compared to Mitomycin C. All P-values are those corrected
using the Benjamini–Hochberg approach for control of false discoveries. P-values marked with an asterisk were found to be significant in the t-
tests but not after false discovery correction. Since they relate to other metabolites in key biological pathways, they are displayed in the table for
reference. GC-MS, gas chromatography–mass spectrometry; LC-MS, liquid chromatography–mass spectrometry; MMC, Mitomycin C; RM, rapamy-
cin.
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Table 4. NT versus MMC.
Associated pathway Metabolite Technique
Target ion m/z
(GC) – MW (LC) RT (min) % Change P-value
Pentose phosphate pathway/glycolysis Pyruvate GC-MS 174 6.7 42 0.02
Lactate GC-MS 147 6.85 34 0.03
Glycerone phosphate GC-MS 315 15.73 72 0.008
Glycerol-1-phosphate GC-MS 357 15.93 56 0.004
Ribulose-5-phosphate GC-MS 357 19.52 72 0.004
Glucose-6-phosphate GC-MS 73 21.31 86 0.001
6-phospho-gluconate GC-MS 73 22.2 49 0.04
Taurine and hypotaurine metabolism Hypotaurine GC-MS 188 14.13 72 0.003
Purine metabolism Hypoxanthine GC-MS 265 16.44 41 0.01
Xanthine GC-MS 353 18.57 57 0.003
Inosine 50-monophosphate GC-MS 315 26.86 56 0.02
TCA cycle Succinate GC-MS 147 10.46 42 0.02
Fumarate GC-MS 245 10.94 46 0.02
Malate GC-MS 147 12.73 49 0.009
(Iso)citrate GC-MS 273 16.54 62 0.007
Arginine and proline metabolism/alanine,
aspartate and glutamate metabolism
Aspartate GC-MS 73 11.94 59 0.002
Aminomalonate GC-MS 73 12.51 54 0.006
(pyro)glutamate GC-MS 156 13.17 58 0.003
Creatinine GC-MS 115 13.58 31 0.04
Glutamine GC-MS 246 14.30 51 0.006
Asparagine GC-MS 73 14.91 56 0.005
Putrescine GC-MS 174 15.71 60 0.009
Ornithine GC-MS 142 16.55 66 0.004
Butanoate metabolism 3-Hydroxybutanoate GC-MS 147 8.29 75 0.0009
Phenylalanine metabolism Phenylalanine GC-MS 120 13.54 48 0.004
Tyrosine GC-MS 179 17.31 56 0.0002
Valine, leucine and isoleucine degradation Valine GC-MS 72 7.3 45 0.004
Leucine GC-MS 86 8.26 57 0.01
Cysteine and methionine metabolism/
glycine, serine and threonine metabolism
Glycine GC-MS 102 7.74 55 0.003
Serine GC-MS 116 9.69 60 0.0003
Methionine GC-MS 104 11.8 73 0.004
Lysine degradation/carnitine metabolism Lysine GC-MS 174 17.64 74 0.0004
L-Octanoylcarnitine LC-MS 287.2089 4.09 27 0.05
Palmitoylcarnitine LC-MS 399.3328 15.87 59 0.002
Fatty acid biosynthesis/beta-alanine
metabolism/lipid metabolism
Uracil GC-MS 241 10.77 48 0.001
O-phosphocolamine GC-MS 73 16.18 53 0.01
Myristate GC-MS 285 16.91 99 0.01
Palmitate GC-MS 117 18.88 114 0.01
Oleate GC-MS 339 20.46 108 0.04
Stearate GC-MS 117 20.69 85 0.01
Acetylspermidine LC-MS 187.1681 0.58 39 0.04
Nonadecadienoate LC-MS 294.2557 26.55 578 0.009
Oxododecenoate LC-MS 212.1407 14.67 403 0.009
PS (40:0) LC-MS 831.622 32.72 43 0.008
PI (37:0) LC-MS 866.6626 21.51 40 0.008
PC (43:6)/PE (46:6) LC-MS 875.6528 32.58 49 0.007
PC (13:1)/PE (16:1) LC-MS 451.2699 18.86 645 0.002
LPE (16:0) LC-MS 437.2913 20.26 142 0.008
LPC (16:1) LC-MS 493.3166 16.91 130 0.002
LPE (18:0) LC-MS 481.3169 23.05 153 0.0005
Metabolites found to be statistically significantly different in the samples that received no treatment compared to Mitomycin C. All P-values are
those corrected using the Benjamini–Hochberg approach for control of false discoveries. GC-MS, gas chromatography–mass spectrometry; LC-MS,
liquid chromatography–mass spectrometry; MMC, Mitomycin C; NT, not treated.
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The concentration of certain prostaglandins was high-
lighted as being significantly different between MMC-trea-
ted tumors and tumors treated either with RM or the
combined MMC + RM treatment. (Glyceryl)prostaglan-
dins were significantly increased by MMC treatment,
while methyl-prostaglandins were relatively reduced. The
abnormal biosynthesis of prostaglandins from fatty acids
has been previously linked with pancreatic cancer devel-
opment (Ding et al. 2003; Ricciotti and FitzGerald 2011).
These are likely to continually increase in the absence of
anti-inflammatory agents. There were no significant dif-
ferences in prostaglandin levels in tumors treated with
MMC compared to nontreated tumors, suggesting that
MMC has no effect. The increase in prostaglandins in
MMC-treated tumors compared to the combined treat-
ment could suggest that the combined treatment involves
an anti-inflammatory response that reduces prostaglandin
levels in these tumors. Methyl-prostaglandins were pres-
ent in higher concentrations in tumors treated with the
combined therapy relative to MMC alone which could be
indicative of the combined therapy utilizing methylation
of prostaglandins in its anti-inflammatory response.
MMC treatment increases the concentration of many
metabolites in pancreatic tumors. Many of these are
involved in CCM and could indicate that MMC directly
inhibits CCM or that in response to the treatment,
tumors focus their metabolism to conserve vital pathways
and suspend extra functions such as lipid biosynthesis.
Figure 3 shows the subnetwork of the metabolic effects of
MMC treatment in pancreatic tumors. Most of these are
increased (highlighted in green) while some are decreased
(highlighted in yellow). The interconnecting pathways
involved in the subnetwork are marked in boxes and con-
necting metabolites that were either not detected or not
found to be significantly altered by treatment with MMC
are shown but are not highlighted. The success of MMC
is likely owed to its action in CCM that is relatively
broad-spectrum (involving various metabolic pathways).
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Figure 3. Metabolic network of tumor response to Mitomycin C (MMC) treatment. Colored metabolites were detected using GC/LC-MS and
those whose concentrations were increased in response to MMC treatment are highlighted in green and those that decreased in yellow. Several
carnitine and (lyso)phospholipids were detected and they are colored to represent the average direction of percentage of change. Metabolites
connected by a single reaction are indicated using solid lines and those connected using a dotted line are connected in the same pathway via a
range of intermediate metabolites not shown.
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